Is the combination of sulfonylureas and metformin associated with an increased risk of cardiovascular disease or all-cause mortality?: a meta-analysis of observational studies - Wikidata - wikimedia - TriplyDB

Is the combination of sulfonylureas and metformin associated with an increased risk of cardiovascular disease or all-cause mortality?: a meta-analysis of observational studies

Is the combination of sulfonylureas and metformin associated with an increased risk of cardiovascular disease or all-cause mortality?: a meta-analysis of observational studies

http://www.wikidata.org/entity/Q36807402

about

Reappraisal of metformin efficacy in the treatment of type 2 diabetes: a meta-analysis of randomised controlled trials Risk of fatal and nonfatal lactic acidosis with metformin use in type 2 diabetes mellitus Risk of fatal and nonfatal lactic acidosis with metformin use in type 2 diabetes mellitus Targeting intensive glycaemic control versus targeting conventional glycaemic control for type 2 diabetes mellitus Complementary and alternative medicine for the treatment of type 2 diabetes Cardiovascular outcome trials for anti-diabetes medication: A holy grail of drug development?The Association between Sulfonylurea Use and All-Cause and Cardiovascular Mortality: A Meta-Analysis with Trial Sequential Analysis of Randomized Clinical Trials Ten-Year Trends in the Morbidity of Diabetes Mellitus and Antidiabetic Drug Utilization in Croatia: A Study Based on Routinely Collected Data.Cardiovascular events and all-cause mortality associated with sulphonylureas compared with other antihyperglycaemic drugs: A Bayesian meta-analysis of survival data.Pioglitazone in addition to metformin improves erythrocyte deformability in patients with Type 2 diabetes mellitus.Is there evidence that oral hypoglycemic agents reduce cardiovascular morbidity/mortality? Yes Effect of metformin on cardiovascular events and mortality: a meta-analysis of randomized clinical trials.Is the ADA/EASD algorithm for the management of type 2 diabetes (January 2009) based on evidence or opinion? A critical analysis Double-blind, placebo-controlled clinical evaluation of an Ayurvedic formulation (GlucoCare capsules) in non-insulin dependent diabetes mellitus.Cardiovascular impact of drugs used in the treatment of diabetes Type 2 diabetes mellitus and the cardiometabolic syndrome: impact of incretin-based therapies.Diabetes: glycaemic control in type 2 (drug treatments).Time to be cautious about prescribing sulfonylureas?Cardiovascular safety of linagliptin in type 2 diabetes: a comprehensive patient-level pooled analysis of prospectively adjudicated cardiovascular events Chinese Herbal Medicine Treatment Improves the Overall Survival Rate of Individuals with Hypertension among Type 2 Diabetes Patients and Modulates In Vitro Smooth Muscle Cell Contractility.Cardiovascular benefits of GLP-1-based herapies in patients with diabetes mellitus type 2: effects on endothelial and vascular dysfunction beyond glycemic control.Critical evaluation of the role of acarbose in the treatment of diabetes: patient considerations.Metformin versus placebo in combination with insulin analogues in patients with type 2 diabetes mellitus-the randomised, blinded Copenhagen Insulin and Metformin Therapy (CIMT) trial.Cardiovascular safety of sitagliptin in patients with type 2 diabetes mellitus: a pooled analysis.Effects of metformin versus glipizide on cardiovascular outcomes in patients with type 2 diabetes and coronary artery disease.Impact of the U.S. Food and Drug Administration cardiovascular assessment requirements on the development of novel antidiabetes drugs.Prescription pattern of chinese herbal products for diabetes mellitus in taiwan: a population-based study Association of hypoglycemic treatment regimens with cardiovascular outcomes in overweight and obese subjects with type 2 diabetes: a substudy of the SCOUT trial A cardiologic approach to non-insulin antidiabetic pharmacotherapy in patients with heart disease.Pathophysiologic approach to therapy in patients with newly diagnosed type 2 diabetes.The treatment of type 2 diabetes.Characteristics of Chinese herbal medicine usage in ischemic heart disease patients among type 2 diabetes and their protection against hydrogen peroxide-mediated apoptosis in H9C2 cardiomyoblasts.Thiazolidinediones and cardiovascular risk - a question of balance.Add-on therapies to metformin for type 2 diabetes.Type 2 diabetes mellitus--current therapies and the emergence of surgical options.Sulfonylureas: do we need to introspect safety again?Review of approved pioglitazone combinations for type 2 diabetes.Linagliptin, a dipeptidyl peptidase-4 inhibitor with a unique pharmacological profile, and efficacy in a broad range of patients with type 2 diabetes.The effect of glucagon-like peptide 1 on cardiovascular risk.Combine and conquer: advantages and disadvantages of fixed-dose combination therapy.

P2860

Q21144611-332FE121-B805-43F5-9BB1-56DDD8C41641 Q24235718-75438BF0-D8D5-4B22-848E-C376174F04A3 Q24240522-75B5FB6D-E688-457C-BF10-5419464D53F0 Q24241529-FC13FA77-7611-40B3-93B1-97260B041F51 Q24648508-A1EACCEC-9FC9-4EE3-8197-61666EC29AF1 Q26740247-F77054A4-172E-4845-8B04-CD8FC3014035 Q26748870-18AE643D-0EA3-4778-B4B9-D3F5579A1D90 Q31117837-25D49A0B-EC19-4935-8014-733B2EEFCFE2 Q31143283-E8FC536D-D50D-496F-867E-D5889BF913D0 Q33590082-EFC35845-EB2B-43CC-8D9A-61F0DB9D6445 Q33610682-EB0B5596-74BB-4370-9225-93CF2431CC44 Q33785313-5DA3A3A7-9C3A-49DF-9491-A9C1D345F950 Q33880174-CF7E3BFA-C818-4DED-A40B-9CD9A259834D Q34206975-40D2418D-019E-4BD9-A305-E26A29A356F3 Q34383575-45C37BD3-2A20-4E56-B7A2-96622BA43E72 Q34620430-7260795C-FF19-4181-ADAC-DCFFDE60B770 Q34829290-EE885B48-719E-498B-BC55-0339DA3EB14A Q35076020-63FD8451-F10F-463A-9DE8-1B357A9DB492 Q35736564-BD56BD55-9FC4-4678-AEC0-105D1FCB3BFD Q35877249-43346EC5-1CF2-447E-9670-8309B5EFAA25 Q35936644-4004F274-A00F-43B6-BAA6-07B1F3327081 Q36333089-9987F012-246F-4F65-A022-8A14E072D539 Q36633074-B81BCC3E-B4B1-4476-935F-58F932AA16E5 Q36649277-FA6B3DDD-164C-4114-8766-E3A7B011D29C Q36782688-66E449FE-B58B-4369-8085-81B335B33246 Q36783681-82ED4D07-7026-4AB1-A0F1-9529D0323FCE Q36988573-10526D55-F710-4068-9568-572351C7DD99 Q37277912-D7AE1CA4-4ACA-4A2F-A39A-8AF8E8002FA3 Q37556648-CF065D72-3347-4EEC-AC42-3E831ED4B03D Q37577162-FBBCF12C-2F2E-4139-8214-EAB82514F38E Q37634244-978DFE45-A711-46B0-B70C-6629C9FC47C3 Q37716571-E924B635-FB30-4A11-9338-70F209AE5912 Q37777027-D1CC4D43-8F29-430D-AA4B-DF02EF8E6054 Q37818234-8D5BBF9F-F3ED-4EB7-BD5A-48756BFF2436 Q37837496-DFFB8F70-EC73-42AA-8633-7FF4E648BAB6 Q37878493-283B53F1-486A-4541-821E-61DC796F6B56 Q37884618-B10B634D-C1ED-44CA-8152-61520847092B Q37965613-92E8467C-1DA9-44AF-AD8C-D694E1573344 Q37980019-E180DEAB-D391-4D86-980F-DF4693C93850 Q38046641-01374EB9-4064-4572-9BB2-CCC318E6CBD0

P2860

Is the combination of sulfonylureas and metformin associated with an increased risk of cardiovascular disease or all-cause mortality?: a meta-analysis of observational studies

http://www.wikidata.org/entity/Q36807402

description

2008 nî lūn-bûn

@nan

2008年の論文

@ja

2008年論文

@yue

2008年論文

@zh-hant

2008年論文

@zh-hk

2008年論文

@zh-mo

2008年論文

@zh-tw

2008年论文

@wuu

2008年论文

@zh

2008年论文

@zh-cn

name

Is the combination of sulfonyl ...... lysis of observational studies

@ast

Is the combination of sulfonyl ...... lysis of observational studies

@en

type

label

Is the combination of sulfonyl ...... lysis of observational studies

@ast

Is the combination of sulfonyl ...... lysis of observational studies

@en

prefLabel

Is the combination of sulfonyl ...... lysis of observational studies

@ast

Is the combination of sulfonyl ...... lysis of observational studies

@en

P1433

Q36807402-E8EBB7A3-E96F-4CC6-9E79-34151D1D54C4

P1476

Q36807402-7C5EED00-2478-4FB7-B755-8D3C3E29CB3B

P2093

Q36807402-4F3BC893-D4C6-4469-96CA-B2CB3E7E5D97

Q36807402-53C0EE35-9801-48EB-A5C8-616CAAA34EC5

Q36807402-A3C1D94E-C619-4060-B77A-AF3B4EEC79A3

P2860

Q36807402-064341C1-633D-41D9-9700-84E40D508E1E

Q36807402-11AB97E9-50D0-4C38-9DEC-AD5691A22A64

Q36807402-13932D8E-19F0-4744-9D1C-51B13D22EB27

Q36807402-13A6ED43-362D-481E-A1D0-071A32DA4FE3

Q36807402-193295C8-49DD-4602-8E15-EB677E1D191A

Q36807402-1F05A540-4177-4CC0-9B6A-1FB178319981

Q36807402-4115869C-A0C1-45F0-B1D4-03BF6081D7D4

Q36807402-4A92BCC2-802F-497D-9BFE-D5EBFFD9ACD7

Q36807402-4B528F9A-B012-40F1-9B03-8E51798FD930

Q36807402-61708C43-C430-45E9-8CA5-844E2E40C4FD

P304

Q36807402-87A40817-CC9B-4502-97BE-B0AD72E09299

P31

Q36807402-04247A7F-CDB9-494F-8ADC-3FCA55B403BB

Q36807402-51f99ffc-8796-4d34-a1df-cbc719f8b3d0

P356

Q36807402-E44F29E6-C530-470A-A162-0D8414F77C02

P407

Q36807402-696741C9-234A-404E-A20C-A2613CEB115E

P433

Q36807402-D561F7EF-D212-4741-AB78-7DC700E411EF

P478

Q36807402-E2E69EC0-4E80-4EFB-95A9-42DE01E6BD52

P50

Q36807402-D6300B67-1F64-4A1E-993F-527828A032E4

P577

Q36807402-86548A79-B5B5-461B-84CE-1901C63EC1FA

P5875

Q36807402-E03D4218-9155-49B8-8CF8-13DBFEB1A8F9

P698

Q36807402-9AA9C322-DAA8-4EDC-82C2-8C809DD1FB41

P921

Q36807402-64DA8B29-2D5F-43D6-8FA0-1E1C1FF50786

Q36807402-94EAA87A-20AB-4233-AE41-7618445D21A4

P932

Q36807402-8D6AFBD5-AB87-4623-8E9A-3C4000EF33D6

P356

P1433

P1476

Is the combination of sulfonyl ...... lysis of observational studies

@en

P2093

Kristi Reynolds

http://www.w3.org/2001/XMLSchema#string

Nitesh Kuhadiya

http://www.w3.org/2001/XMLSchema#string

Vivian A Fonseca

http://www.w3.org/2001/XMLSchema#string

P2860

Systematic Review: Comparative Effectiveness and Safety of Oral Medications for Type 2 Diabetes Mellitus

Effect of Rosiglitazone on the Risk of Myocardial Infarction and Death from Cardiovascular Causes

Bias in meta-analysis detected by a simple, graphical test

Operating characteristics of a rank correlation test for publication bias

Meta-analysis in clinical trials

Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group

Editorial: sulfonylureas differ in effects on ischemic preconditioning--is it time to retire glyburide?

Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group

Effects of intensive glucose lowering in type 2 diabetes

Rosiglitazone evaluated for cardiovascular outcomes--an interim analysis.

P304

1672-1678

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.2337/DC08-0167

http://www.w3.org/2001/XMLSchema#string

P407

P433

8

http://www.w3.org/2001/XMLSchema#string

P478

31

http://www.w3.org/2001/XMLSchema#string

P50

P577

2008-05-05T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

5395137

http://www.w3.org/2001/XMLSchema#string

P698

18458139

http://www.w3.org/2001/XMLSchema#string

P921

cardiovascular disease

P932

2494623

http://www.w3.org/2001/XMLSchema#string